A Phase 1 interventional study of [14C]Zorifertinib Oral Formulation in EGFR Mutant Advanced Non-small Cell Lung Cancer and Central Nervous System (CNS) Metastases, sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.
Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 398th largest by enrollment of the 403 interventional ones that give a count, is one of 64 that started in 2026, is one of 93 in phase 1, and was the 457th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:
Genovn Therapeutics (Suzhou) Co., Ltd. · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
Nanjing Medical University · Sites in China
Ages 18–80
Fudan University · Sites in China
Ages 18–75
Taizhou Mabtech Pharmaceutical Co.,Ltd · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
487 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 171 · Phase 3 85 · Phase 4 13
First in 2003; this study’s year is marked. 64 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 90 across the 403 interventional studies, 180 across the 83 observational. Of the 104 that completed or were terminated, 27 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 487 have an industry lead sponsor. The 10 most frequent:
Alpha Biopharma (Jiangsu) Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Alpha Biopharma (Jiangsu) Co., Ltd. has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
81 of the studies in Neoplasm Metastasis with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT05794971Phase 3Sun Yat-sen UniversityRegorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases | 2027-03-31 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06961188Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis | 2027-06-30 |
Add all 81 to your calendar (.ics) → With an account.
Among the 487 studies in Neoplasm Metastasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of [14C]Zorifertinib in healthy Chinese adult male participants. The study includes a screening period (Day -14 to Day -1) and a dosing and observation period (Day 1 to Day 14). Blood, urine, and feces samples will be collected to measure radioactivity, drug concentrations, and metabolites. Safety will be assessed by adverse events, vital signs, laboratory tests, 12-lead ECG, and ophthalmic examinations. The target total radioactivity recovery is ≥90% of the administered dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ancillary Examinations:
Abnormal findings from ophthalmic examination (slit lamp, intraocular pressure, fundus photography) that are clinically significant.
Medication History:
Use of any prescription drugs, over-the-counter drugs, herbal medicines, or food supplements (e.g., vitamins, calcium supplements) within 14 days prior to the screening period.
Medical and Surgical History:
Hemorrhoids or perianal diseases with regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease.
Lifestyle Habits:
Habitual consumption of grapefruit juice or excessive tea, coffee, and/or caffeinated beverages, and inability to abstain during the study period.
Others:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: [14C]Zorifertinib Oral Formulation
Single oral administration of 200 mg/5 µCi \[¹⁴C\]Zorifertinib in healthy male subjects under fasting condition
Total radioactive recovery and cumulative total radioactive recovery in urine and feces at each time interval
Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met
Percentage of total radioactivity exposure (%AUC), percentage of parent drug and its metabolites (%Dose), and metabolite identification
Percentage of total radioactivity exposure (%AUC) accounted for by parent drug and its metabolites in plasma. Percentage of administered dose (%Dose) accounted for by parent drug and its metabolites in urine and faeces. Identification of metabolites in plasma, urine, and feces
Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met
Peak Plasma Concentration (Cmax)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Time to Peak Concentration (Tmax)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Elimination Half-Life (t1/2)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Terminal Rate Constant (λz)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Apparent Volume of Distribution (Vz/F)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Apparent Clearance (CLz/F)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Mean Residence Time (MRT)
Pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable)
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Whole blood / plasma total radioactivity ratio
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Peak Plasma Concentration (Cmax)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Time to Peak Concentration (Tmax)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Elimination Half-Life (t1/2)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Terminal Rate Constant (λz)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Apparent Volume of Distribution (Vz/F)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Apparent Clearance (CLz/F)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Mean Residence Time (MRT)
Pharmacokinetic parameters for zorifertinib, its metabolite (AZ'1168), and other major metabolites (if applicable) in plasma
Time frame: Pre-dose up to 120 hours after dosing,or until termination criteria met
Incidence and severity of Adverse Events (AEs)
All adverse events were classified according to the CTCAE (version: 6.0)
Time frame: Pre-dose up to 312 hours after dosing, or until termination criteria met
Ran from Jul 2026 to primary completion in Jul 2026, 0 months.
Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 0 months is below that.
Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alpha Biopharma (Jiangsu) Co., Ltd.